Arbutus Biopharma Corp (ABUS) income statement
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 14/3073% below fair value
$4.05+0.01 (+0.25%)
Close on Nov 17, 2026Market cap $801.28MP/E 5.2Yield –
Arbutus Biopharma Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 82.0%
- Net margin
- 84.2%
- Return on equity, FY2025
- -38.5%
Financial strength
- Current ratio
- 81.42
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 569.9%
Valuation
- P/E ratio
- 5.2
- Price to sales
- 4.41
- Price to book
- 3.10
- Dividend yield
- –
See a number that looks wrong?